Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. S.K. — Clinical Trial Site

42 Registered trials

16 Currently recruiting

Organisation

Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. S.K.

Location

Oswiecim, Poland

Identifier

ORG-100042991

Address

Ul. Gen. Jaroslawa Dabrowskiego 4, 32-600, Poland

Departments

-
#40535: N/A
#616003 Neurologia
616008: neurology
616015: neurology
Chronic pain
Dermatology
Instytut Zdrowia Dr Boczarska- Jedynak Sp. z o.o. S.k.
Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o., Sp. k.
KLINIKA NEUROLOGII I MEDYCYNY REGENERACYJNEJ
N/A
NA
Neurology
not applicable/nie dotyczy
Poradnia dermatologiczna i wenerologiczna, dział badań klinicznych
Poradnia Neurologiczna
unknown

Clinical trials at this site (42)

Search interface

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting

2024-520098-12-00 Cutaneous Lupus Erythematosus 4 2026-02-16
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P… Recruiting

2024-514617-35-00 Progressive forms of Multiple Sclerosis 4 2021-12-20
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting

2024-511101-28-00 Episodic Migraine Chronic Migraine 4 2026-02-24
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
C4951063: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Recruiting

2024-517121-10-00 Menstrual Migraine 5 2025-10-17
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Chronic migraine 5 2025-10-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Episodic migraine 5 2025-10-06
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo… Recruiting

2025-520499-24-00 Moderate to Severe Platysma Prominence 5 2025-10-01
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasti… Recruiting

2024-517745-14-00 Multiple Sclerosis Spasticity 4 2025-09-24
A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting

2024-519248-34-00 Cervical Dystonia 4 2025-06-17
A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting

2022-502917-27-00 Migraine 5 2023-03-07
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting

2024-510656-13-00 Migraine 5 2022-11-08
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Upper limb spasticity after stroke or traumatic brain i 7 2021-04-29
A trial of Lu AF82422 in Participants with Multiple System Atrophy (MSA) Ended

2024-517169-18-00 Multiple System Atrophy 5 2025-04-10
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Chronic migraine 5 2024-03-18
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Episodic Migraine 5 2024-03-18
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17